9th International MDM2 Workshop Meeting Agenda

Don CeSar Hotel, St. Pete Beach, Florida U.S.A
November 4-7, 2018 

9th International MDM2 Workshop Topics

MDM2 and MDMX in stress response
Regulation of MDM2 and MDMX
Mouse models of MDM2 and MDMX
MDM2 and MDMX control of p53
p53-independent roles for MDM2 and MDMX
MDM2, MDMX and p53 as therapeutic targets
MDM2 and MDMX in human disease

Sunday, November 4th  

2:00 PM 6:30 PM Registration
6:30 PM 6:45 PM Welcome
Chen, Cleveland, Flores 
6:45 PM 7:00 PM

Opening Remarks

Sir David Lane

7:00 PM 7:50 PM

Keynote talk 1
Guillermina Lozano

The Mdm Network: a rheostat for p53 activity in development and cancer
7:50 PM 9:30 PM Reception

Monday, November 5th 

7:00 AM 8:00 AM Breakfast
8:00 AM 8:50 AM

Keynote talk 2

Carol Prives

p53-dependent and independent roles of Mdm2 and MdmX in human cancer cells


8:50 AM 9:15 AM Sir David Lane. Title TBD
9:15 AM 9:40 AM

Aart Jochemsen. Novel oncogenic function of Mdmx: inhibition of FOXO tumor suppressor activity

9:40 AM 10:05 AM Hua Lu. New Regulators of the MDM2-p53 Loop
 10:05 AM  10:25 AM  Coffee break
10:25 AM 10:50 AM Wei Gu. Dissecting a novel pathway in p53-mediated tumor suppression
10:50 AM 11:15 AM Ygal Haupt. Targeting MDM4 in prostate and breast cancers: does p53 status matter?
11:15 AM 11:40 AM Matthias Dobbelstein.  Control of DNA replication forks - p53, Mdm2, and chromatin modifications
11:40 AM 12:05 AM Xinbin Chen.  The role of the p53-Mdm2-FDXR loop in cellular iron homeostasis 
12:05 PM 1:00 PM Lunch
1:00 PM 2:00 PM Poster session+coffee break
2:00 PM 2:25 PM Laura Attardi.  Deconstructing the Phenotypic Complexity Underlying p53-Associated Developmental Syndromes
2:25 PM 2:50 PM Elsa Flores.  Therapeutic implications of cross talk between the p53 family and mdm2-like proteins
2:50 PM 3:15 PM Ute Moll.  Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion
3:15 PM 3:40 PM Franck Toledo.  p53 signalling in bone marrow failure syndromes
3:40 PM 3:55 PM Coffee break
3:55 PM 4:20 PM Jim Manfredi.  Regulation of mitosis by p53 and Mdm2 in vivo
4:20 PM 4:45 PM Yanping Zhang.  In vivo, MDMX is essential in MDM2 mediated p53 degradation
4:45 PM 5:00 PM John Parant.  Defining the mechanism of p53 tumor suppression through MDM2 null embryonic lethality
5:00 PM 5:15 PM Erwin Van Meir. BAI1 acts as a tumor suppressor in medulloblastoma by sequestering mdm2 from p53
5:15 PM 5:30 PM Wenwei Hu.  p53 codon 72 polymorphism affects aging and longevity in mouse models
6:15 PM 10:15 PM Bus to dinner cruise

Tuesday, November 6th 

7:00 AM 8:00 AM Breakfast
8:00 AM 8:25 AM Joaquin Espinosa.  Novel mechanisms defining the cellular response to MDM2 inhibitors
8:25 AM 8:50 AM Zhixiong Xiao. MDMX targets retinoblastoma protein in regulation of cellular senescence and embryonic stem cell differentiation
8:50 AM 9:15 AM Danny Huang.  E3-independent function of MDM2 in p53 regulation
9:15 AM 9:30 AM Gary Daughdrill.  Protein disorder controls the p53 network
9:30 AM 9:45 AM Ashish Lal.  A novel circular RNA from the MDM2 locus facilitates cell cycle progression by suppressing p53 levels
9:45 AM 10:05 AM Coffee break
 10:05 AM 10:30 AM  Laetitia Linares.  MDM2 and Metabolism: new therapeutic strategies for liposarcoma
10:30 AM 10:55 AM Zhaohui Feng.  p53 target E3 ubiquitin ligase Parkin inhibits glycolysis and cancer metastasis
10:55 AM 11:10 AM James DeCaprio.  Dual Inhibition of MDM2 and MDM4 in Virus-Positive Merkel Cell Carcinoma Enhances the p53 Response
11:10 AM 11:25 AM Steven Grossman.  DBC1 stabilizes p53 via inhibition of CBP-dependent p53 polyubiquitination
11:25 AM 11:40 AM Lindsey Mayo.  Mdm2 promotes Angiogenesis through the regulation of pVHL
12:00 PM 1:00 PM Lunch
1:00 PM 2:00 PM Poster session+coffee break
2:00 PM 2:25 PM Benjamin Beckermann. Title TBD
2:25 PM  2:50 PM Michael Andreeff.  MDM2 as Therapeutic Target in Leukemias
2:50 PM 3:15 PM Klas Wiman.  Cancer therapy by targeting missense and nonsense mutant p53
3:15 PM 3:40 PM David Sallman.  Evolving clinical data on APR-246 in TP53 mutant myelodysplastic syndrome and acute myeloid leukemia
3:40 PM 3:55 PM Coffee break
3:55 PM 4:20 PM Manuel Aivado. Dual inhibition of MDMX and MDM2 with the stapled alpha-helical peptide ALRN6924
4:20 PM 4:45 PM Shaomeng Wang.  Discovery of Highly Potent and Efficacious PROTAC MDM2 Degraders 
4:45 PM 5:10 PM Ruiwen Zhang.  Dual NAFT1 and MDM2 inhibitors for Cancer Therapy
5:10 PM 5:25 PM Wuyuan Lu.  Peptide activators of p53 for cancer therapy
5:25 PM 6:30 PM Break
6:30 PM 9:30 PM Workshop dinner

Wednesday, November 7th 

7:00 AM 8:00 AM Breakfast
8:00 AM 8:25 AM Zhimin Yuan.  A critical role of JNK/MDMX-dependent p53 inhibition in HFD-induced metabolic disorders
8:25 AM 8:50 AM Christine Eischen.  Targeting Mdm2 as a novel treatment for p53-inactivated cancers
8:50 AM 9:15 AM Galina Selivanova.  Unraveling the mechanisms of action of p53-activating compounds
9:15 AM 9:30 AM Loren Walensky.  Reactivation of p53-mediated apoptosis in pediatric cancers by a stapled peptide inhibitor of HDM2 and HDMX
9:30 AM 9:50 AM Coffee break
9:50 AM 10:15 AM Robin Fahraeus.  MDM2 and the Epstein-Barr virus: A blast from the past with an oncogenic mRNA in the cast
10:15 AM 10:40 AM Jill Bargonetti.  Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer
10:40 AM 11:05 AM Jiandong Chen.  Tumor-derived CK1 alpha mutations enhance MDMX inhibition of p53
11:05 AM 11:20 AM Dawn Chandler.  MDM2 alternative splicing is regulated by microRNA binding: A novel pathway of MDM2 regulation
11:20 AM 11:55 PM Arnold Levine.  Meeting summary
12:00 PM 1:00 PM Lunch and departure